Drug Interactions between moxetumomab pasudotox and sulfasalazine
This report displays the potential drug interactions for the following 2 drugs:
- moxetumomab pasudotox
- sulfasalazine
Interactions between your drugs
sulfaSALAzine moxetumomab pasudotox
Applies to: sulfasalazine and moxetumomab pasudotox
MONITOR: Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of 5-aminosalicylate or its prodrugs has been associated with rare reports of renal impairment including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure. Animal studies have also shown the kidney to be the major target organ of 5-aminosalicylate toxicity. Renal lesions including granular and hyaline casts, tubular degeneration, tubular dilation, renal infarct, papillary edema, papillary necrosis, tubular necrosis, interstitial fibrosis, and interstitial nephritis have been observed with large doses.
MANAGEMENT: Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during 5-aminosalicylate therapy.
References
- Novis BH, Korzets Z, Chen P, Bernheim J (1988) "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed), 296, p. 1442
- "Product Information. Canasa (mesalamine)." Axcan Pharma US Inc
- (2022) "Product Information. Lialda (mesalamine)." Shire US Inc
- Schreiber S. Hamling J, Zehnter E, et al. (1997) "Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate." Gut, 40, p. 761-6
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.